P1‐050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAY‐OF‐ONSET PHASE 3 CLINICAL TRIAL

Carl Chiang, PhD1, Robert Alexander, MD2, Kathleen A. Welsh-Bohmer, PhD3,4, Brenda L. Plassman, PhD3,4, Heather Romero, PhD3, Kathleen M. Hayden, PhD3,4, Richard S.E. Keefe, PhD4, 5, Alexandra S. Atkins, PhD5, Patrick Harrigan, BChE6*, Janet O’Neil, MBA6, Meredith Culp, BS6, Ryan Walter, BS7, Jingtao Wu, PhD6, LaDonna Randle, BA7, Stephen Haneline, MS1, Deborah Yarbrough, MS, MBA6, Daniel K. Burns, PhD1, Ann M. Saunders, PhD1, for the TOMMORROW Study Investigators 1Zinfandel Pharmaceuticals, Inc., Durham, NC, USA; 2Takeda Development Center Americas, Inc., Cambridge, MA, USA; 3Duke University Bryan ADRC, Durham, NC, USA; 4Department of Psychiatry, Duke University Medical Center, Durham, NC, USA; 5NeuroCog Trials, Durham, NC, USA; 6Takeda Development Center Americas, Inc., Deerfield, IL, USA; 7PRA Health Science, Deerfield, IL, USA